Sagimet Biosciences Inc. Share Price & Technical Analysis
SGMT · $7.22 (+1.83%)
Healthcare / Biotechnology
$7.22
+1.83%
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunc…
Price chart
Seasonality
May has 1 positive and 1 negative years (last 4 years shown)
-12% return in May, 18% avg return in past 3 year May month.
31% return in 2026, 11% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 0% | -5% | 54% | -12% | – | – | – | – | – | – | – | 31% |
| 25 | -2% | -12% | -11% | 6% | 0% | 117% | 14% | -13% | -8% | 23% | -15% | -17% | 83% |
| 24 | 79% | -36% | -13% | -30% | 36% | -37% | 0% | -9% | -7% | 37% | 10% | -20% | 10% |
| 23 | – | – | – | – | – | – | 3% | -20% | -28% | -57% | 3% | 42% | -58% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$460.04M
P/E ratio
—
52W high
$11.41
52W low
$3.32
Volume
9,07,385
Beta
3.64
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Sagimet Biosciences Inc. share price today?
- Sagimet Biosciences Inc. (SGMT) last traded around $7.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SGMT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SGMT. Download the app for real-time alerts.
- How can I analyze Sagimet Biosciences Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.